Pulmonary fibrosis is a progressive lung disease that its pathogenic mechanism currently is
incompletely understood. Toll-like receptor (TLR) signaling has recently been identified as a …

Growing evidence suggests a mechanistic link between inflammation and the development
and progression of fibrotic processes. Mesenchymal stromal cells derived from the human …

Background Pulmonary fibrosis (PF) is a growing clinical problem with limited therapeutic
options. Human umbilical cord mesenchymal stromal cell (hucMSC) therapy is being …

Background Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease that
has no cure. Although mesenchymal stem cells (MSCs) have been reported to ameliorate …

Background Idiopathic pulmonary fibrosis is a kind of diffuse interstitial lung disease, the
pathogenesis of which is unclear, and there is currently a lack of good treatment to improve …

Interstitial lung disease (ILD) involves persistent inflammation and fibrosis, leading to
respiratory failure and even death. Adult tissue-derived mesenchymal stem cells (MSCs) …

Background Interstitial pneumonia in connective tissue diseases (CTD-IP) featuring
inflammation and fibrosis is a leading cause of death in CTD-IP patients. The related …

Background Idiopathic pulmonary fibrosis (IPF) is a devastating disease characterized by
the histopathological pattern of usual interstitial pneumonia and is associated with a high …

Pulmonary fibrosis is a chronic progressive lung disease with few treatments. Human
mesenchymal stem cells (MSCs) have been shown to be beneficial in pulmonary fibrosis …

Objective To investigate the influence of human placenta mesenchymal stem cells
(hPMSCs) on the expression levels of inflammatory factors in the lung tissues of …